Researchers are finding that antigens from the microbiota may play a role in the development of autoimmunity.
Race As a Risk Factor for Sjögrens Syndrome
A new study in Arthritis Care & Research highlights potential differences in incidence, the presentation of prominent symptoms and laboratory findings in African Americans and Native Americans with Sjögren’s syndrome compared with white populations. Native Americans appear to be at higher risk of the disease, although they often display fewer of the classic symptoms. Importantly,…
Changes in ICD-10 for Sjögren’s Syndrome
A code change in the ICD-10 classification for Sjögren’s syndrome was approved by the ICD-10 Coordination and Maintenance Committee in July 2019 and becomes effective October 2020.
Hope for Live Births in Women with Antiphospholipid Syndrome
For women with antiphospholipid syndrome (APS), treatment with a combination of heparin and aspirin during pregnancy—rather than aspirin alone—may increase live birth rates, according to new research.
Study Provides Clues to Undefined, Systemic, Autoinflammatory Diseases
A study from October 2019 describes the clinical characteristics of pediatric patients with undefined systemic autoinflammatory diseases. Researchers conducted a genetic analysis and outlined specific variants. They found patients with pericarditis and intellectual impairment may have distinct clinical phenotypes, which may lead to improved diagnostic and treatment options.
After COVID-19-Associated MIS-C, Immune Changes Resolve
NEW YORK (Reuters Health)—A new study of multisystem inflammatory syndrome in children (MIS-C) shows that the immune system is profoundly altered during acute illness, but gradually returns back to normal. MIS-C is distinct from both COVID-19 and Kawasaki disease, but is associated with previous SARS-CoV-2 infection, the immunological profiling study reveals. Dr. Manu Shankar-Hari, an…
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
FDA Approves Canakinumab for Adult-Onset Still’s Disease
Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
The ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic.
Serum Interleukin 6 Levels May Predict Presentation of IgG4-Related Disease
A retrospective study found serum interleukin 6 levels at the onset of IgG4-RD may significantly correlate with clinical inflammatory parameters and the involvement of the bile duct, liver and spleen…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 33
- Next Page »